<div id="readability-page-1"><div> Health-care companies rose as defensive-minded traders rotated into the sector, which is viewed as relatively evergreen. Precious metals had been the preferred safe haven during recent domestic and geopolitical instability. Traders abruptly fled those investments following the unveiling of former Federal Reserve governor Kevin Warsh as President Trump's Fed nominee. Warsh was a much more conventional and possibly less dovish choice than market participants had anticipated. Drug giant Eli Lilly unveiled plans to open a $3.5 billion plant to produce weight-loss drugs in Pennsylvania's Lehigh Valley, giving the region an economic shot in the arm. British drug maker AstraZeneca said it entered into a collaboration agreement with China's CSPC Pharmaceuticals to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs, in a deal potentially valued at billions of dollars. Pfizer and Merck rose ahead of earnings next week. Health insurers remained under pressure due to concerns about the Trump administration's proposed rates for Medicare reimbursement. <pre></pre> Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires January 30, 2026 17:46 ET (22:46 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

300765

IBBQ

Health-care stocks increased as traders shifted focus to the sector amid market instability. Eli Lilly announced a $3.5 billion plant for weight-loss drugs in Pennsylvania, while AstraZeneca partnered with CSPC Pharmaceuticals for obesity and diabetes drug rights. Pfizer and Merck saw gains ahead of upcoming earnings, but health insurers faced pressure from proposed Medicare reimbursement rates by the Trump administration.

- Health-care companies saw an increase as traders shifted towards the sector due to its perceived stability amidst unrest.  
- Eli Lilly announced plans for a $3.5 billion weight-loss drug plant in Pennsylvania, while AstraZeneca partnered with CSPC Pharmaceuticals on an obesity and diabetes drug portfolio valued in billions.  
- Concerns about the Trump administration's proposed Medicare reimbursement rates continued to pressure health insurers ahead of upcoming earnings reports from Pfizer and Merck.

MorningStar

VanEck Biotech ETF

CSPC Innovation

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Pfizer

iShares US Pharma

Ark Genomic Revolution ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Eli Lilly

VG Health

Merck

Health Care Up After Defensive Rotation — Health Care Roundup